Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome

Last updated: August 22, 2017
Sponsor: Laboratoires Thea
Overall Status: Completed

Phase

3

Condition

Sjogren's Syndrome

Eye Disease

Dry Eye Disease

Treatment

N/A

Clinical Study ID

NCT02023268
LT2762-PIII-08/13
2013-A01292-43
  • Ages > 18
  • All Genders

Study Summary

Comparison of the efficacy and safety of T2762 and Vismed® in the treatment of moderate to severe Dry Eye Syndrome

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Signed and dated informed consent

  • Male or female aged from ≥ 18 years old.

  • Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior tostudy selection.

Exclusion

Exclusion Criteria:

  • Best far corrected visual acuity < 1/10

  • Severe blepharitis

  • Severe Dry Eye

Study Design

Total Participants: 105
Study Start date:
December 01, 2013
Estimated Completion Date:
February 28, 2015

Connect with a study center

  • Clermont-Ferrand,
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.